Accordingly, targeting EGFR protein has been suggested as a promising strategy for targeted cancer therapy, since the EGFR is commonly overexpressed in many human cancers, including non-small cell lung, head, breast, bladder and ovarian carcinoma [12,13]. This evidence concerns the gene EGFR and ovarian carcinoma.